224 related articles for article (PubMed ID: 20630403)
1. Mediators of anemia in chronic heart failure.
Le Jemtel TH; Arain S
Heart Fail Clin; 2010 Jul; 6(3):289-93. PubMed ID: 20630403
[TBL] [Abstract][Full Text] [Related]
2. Pathophysiology of anemia in heart failure.
Anand IS
Heart Fail Clin; 2010 Jul; 6(3):279-88. PubMed ID: 20630402
[TBL] [Abstract][Full Text] [Related]
3. Erythropoietin in heart failure.
Silverberg DS; Wexler D; Blum M; Iaina A; Sheps D; Keren G; Schwartz D
Semin Nephrol; 2005 Nov; 25(6):397-403. PubMed ID: 16298262
[TBL] [Abstract][Full Text] [Related]
4. Outcomes associated with anemia in patients with heart failure.
Salisbury AC; Kosiborod M
Heart Fail Clin; 2010 Jul; 6(3):359-72. PubMed ID: 20630410
[TBL] [Abstract][Full Text] [Related]
5. The interaction between heart failure and other heart diseases, renal failure, and anemia.
Silverberg DS; Wexler D; Iaina A; Schwartz D
Semin Nephrol; 2006 Jul; 26(4):296-306. PubMed ID: 16949468
[TBL] [Abstract][Full Text] [Related]
6. Therapy insight: congestive heart failure, chronic kidney disease and anemia, the cardio-renal-anemia syndrome.
Iaina A; Silverberg DS; Wexler D
Nat Clin Pract Cardiovasc Med; 2005 Feb; 2(2):95-100. PubMed ID: 16265380
[TBL] [Abstract][Full Text] [Related]
7. Anemia and chronic heart failure implications and treatment options.
Anand IS
J Am Coll Cardiol; 2008 Aug; 52(7):501-11. PubMed ID: 18687241
[TBL] [Abstract][Full Text] [Related]
8. Disordered iron homeostasis in chronic heart failure: prevalence, predictors, and relation to anemia, exercise capacity, and survival.
Okonko DO; Mandal AK; Missouris CG; Poole-Wilson PA
J Am Coll Cardiol; 2011 Sep; 58(12):1241-51. PubMed ID: 21903058
[TBL] [Abstract][Full Text] [Related]
9. The role of anemia in the progression of congestive heart failure. Is there a place for erythropoietin and intravenous iron?
Silverberg DS; Wexler D; Iaina A
J Nephrol; 2004; 17(6):749-61. PubMed ID: 15593047
[TBL] [Abstract][Full Text] [Related]
10. Cardiorenal anemia syndrome: do erythropoietin and iron therapy have a place in the treatment of heart failure?
Pagourelias ED; Koumaras C; Kakafika AI; Tziomalos K; Zorou PG; Athyros VG; Karagiannis A
Angiology; 2009; 60(1):74-81. PubMed ID: 18413330
[TBL] [Abstract][Full Text] [Related]
11. The correction of anemia in severe resistant heart failure with erythropoietin and intravenous iron prevents the progression of both the heart and the renal failure and markedly reduces hospitalization.
Silverberg DS; Wexler D; Blum M; Tchebiner J; Sheps D; Keren G; Schwartz D; Baruch R; Yachnin T; Shaked M; Zubkov A; Steinbruch S; Iaina A
Clin Nephrol; 2002 Jul; 58 Suppl 1():S37-45. PubMed ID: 12227725
[TBL] [Abstract][Full Text] [Related]
12. Management of anemia in heart failure.
Stamos TD; Silver MA
Curr Opin Cardiol; 2010 Mar; 25(2):148-54. PubMed ID: 19996965
[TBL] [Abstract][Full Text] [Related]
13. Future directions in management of anemia in heart failure.
Agarwal AK; Katz SD
Heart Fail Clin; 2010 Jul; 6(3):385-95. PubMed ID: 20630412
[TBL] [Abstract][Full Text] [Related]
14. Intravenous iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency.
Toblli JE; Lombraña A; Duarte P; Di Gennaro F
J Am Coll Cardiol; 2007 Oct; 50(17):1657-65. PubMed ID: 17950147
[TBL] [Abstract][Full Text] [Related]
15. Are hematinic deficiencies the cause of anemia in chronic heart failure?
Witte KK; Desilva R; Chattopadhyay S; Ghosh J; Cleland JG; Clark AL
Am Heart J; 2004 May; 147(5):924-30. PubMed ID: 15131553
[TBL] [Abstract][Full Text] [Related]
16. Erythropoietin improves anemia exercise tolerance and renal function and reduces B-type natriuretic peptide and hospitalization in patients with heart failure and anemia.
Palazzuoli A; Silverberg D; Iovine F; Capobianco S; Giannotti G; Calabrò A; Campagna SM; Nuti R
Am Heart J; 2006 Dec; 152(6):1096.e9-15. PubMed ID: 17161060
[TBL] [Abstract][Full Text] [Related]
17. Factor deficiency in the anemia of renal transplant patients with grade III-IV chronic kidney disease: baseline results of the ARES Study.
Gentil MA; Pérez-Valdivia MA; López-Mendoza M; Ortega F; Arias M; Gómez-Alamillo C; Campistol JM;
Transplant Proc; 2008 Nov; 40(9):2922-4. PubMed ID: 19010148
[TBL] [Abstract][Full Text] [Related]
18. Pathogenesis of anemia in cardiorenal disease.
Anand IS
Rev Cardiovasc Med; 2005; 6 Suppl 3():S13-21. PubMed ID: 16340934
[TBL] [Abstract][Full Text] [Related]
19. The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations.
Silverberg DS; Wexler D; Blum M; Keren G; Sheps D; Leibovitch E; Brosh D; Laniado S; Schwartz D; Yachnin T; Shapira I; Gavish D; Baruch R; Koifman B; Kaplan C; Steinbruch S; Iaina A
J Am Coll Cardiol; 2000 Jun; 35(7):1737-44. PubMed ID: 10841219
[TBL] [Abstract][Full Text] [Related]
20. Biomarkers for chronic heart failure.
Lainscak M; von Haehling S; Springer J; Anker SD
Heart Fail Monit; 2007; 5(3):77-82. PubMed ID: 17487296
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
